Dyskinesias clinical trials

The registry lists 179 studies for Dyskinesias across more than 10 countries. 24 are recruiting or about to start. 49 of them are mainly about Dyskinesias (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-30. Counting its 16 narrower conditions too, such as Huntington Disease: 1,597 studies, 301 open.

Get an email when these change. Save the Dyskinesias studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 103
Terminated: 27
Status unknown: 16
Recruiting: 16
Not yet recruiting: 6
Withdrawn: 3

Phase

Phase 2: 56
Phase 3: 33
Phase 1: 17
Phase 4: 7

Where

United States: 101
Germany: 30
France: 28
Canada: 23
Spain: 22
Italy: 17

Who runs them

National Institute of Neurological Disorders and Stroke (NINDS) (13) · Novartis Pharmaceuticals (7) · Adamas Pharmaceuticals, Inc. (6) · Oregon Health and Science University (6) · Great Lakes NeuroTechnologies Inc. (6) · AbbVie (prior sponsor, Abbott) (5) · Novartis (5) · CardioKinetix, Inc (4)

What is being tested here

Drugs under test in Dyskinesias studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
TRK 820	1	0	1
Nicotinamide-beta-riboside	1	0	1
Rivaroxaban	1	0	1
Mavoglurant	0	0	9
Amantadine	0	2	7
Levodopa	0	4	7
Carbidopa	0	4	5
Sarizotan	0	2	4
Deutetrabenazine	0	3	3
JM-010	0	0	3

Drug classes tested here Dopamine agonists 6 · Serotonin receptor agonists 3

Coming up

2phase 3 studies under way

6studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6

Dec 2026Connectomic Guided DBS for Parkinson's Disease · Duke University
Feb 2027Oscillatory Activity in Basal Ganglia Circuits During Normal and Pathological Movement · University Hospital, Bordeaux
Apr 2027Parkinsonism-Related Oscillations in the Cortico-Basal Ganglia-Thalamic Network During Movement: Beyond the Frequency Range · University Hospital, Bordeaux
May 2027rTMS as an Intervention for Levodopa-induced Dyskinesia · Danish Research Centre for Magnetic Resonance
May 2027Adaptive DBS for PD · Beijing Pins Medical Co., Ltd
Sep 2027A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations · Appello Pharmaceuticals, Inc.

Who these studies take

Of the 16 Dyskinesias studies recruiting now, 4 (25%) set no upper age limit and 8 (50%) stop at 75 or younger. 5 (31%) take children under 18. 1 (6%) are for women only and 0 (0%) for men only; 2 (13%) take healthy volunteers.

Recruiting studies that take each age, of 16
Age	Women	Men
10	5 (31%)	5 (31%)
18	13 (81%)	13 (81%)
30	13 (81%)	12 (75%)
40	13 (81%)	12 (75%)
50	12 (75%)	12 (75%)
65	12 (75%)	12 (75%)
75	12 (75%)	12 (75%)
85	4 (25%)	4 (25%)

Across all 179 studies, recruiting or not: 23% stop at 75 or younger and 11% at 65; 19% take children; 1% are for women only and 0% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered1

Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated DyskinesiaOct 30, 2026NCT07905976

Studies

Recruiting first, then most recently updated. Showing 50 of 179. Browse all 179 → or search them.